Penserra Capital Management LLC Supernus Pharmaceuticals, Inc. Transaction History

Penserra Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$26.37 - $34.22 $32,039 - $41,577	-1,215 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $235 - $313	10 Added 0.83%	1,215 $32,000
Q2 2021 Aug 12, 2021	BUY	$26.72 - $33.19 $400 - $497	15 Added 1.26%	1,205 $37,000
Q1 2021 May 13, 2021	SELL	$24.15 - $31.45 $483 - $629	-20 Reduced 1.65%	1,190 $31,000
Q4 2020 Feb 12, 2021	BUY	$17.7 - $25.81 $13,416 - $19,563	758 Added 167.7%	1,210 $30,000
Q3 2020 Nov 13, 2020	BUY	$20.2 - $25.05 $9,130 - $11,322	452 New	452 $9,000
Q3 2018 Nov 05, 2018	SELL	$42.7 - $56.55 $10.4 Million - $13.8 Million	-244,371 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$44.1 - $59.85 $10.8 Million - $14.6 Million	244,371 New	244,371 $29 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.06B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.